Metformin C4 Health (Metformin Hydrochloride)

Metformin lowers blood sugar by inhibiting hepatic glucose production, reducing intestinal glucose absorption, and enhancing peripheral insulin sensitivity through activation of AMP‑activated protein kinase (AMPK). These mechanisms lower circulating glucose without increasing insulin secretion.

The dosage of Metformin C4 Health is determined by the prescribing clinician based on the individual’s renal function, glycemic targets, and tolerability. Patients should follow the dose regimen provided by their healthcare professional.

Safety of metformin during pregnancy or lactation should be evaluated by a healthcare professional. While some guidelines allow limited use when benefits outweigh risks, the decision must be individualized and discussed with the prescriber.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Metformin belongs to the biguanide class and is often first‑line therapy for type 2 diabetes because of its efficacy, low risk of hypoglycemia, and favorable impact on weight. Compared with sulfonylureas or insulin, metformin does not stimulate insulin release and has a different side‑effect profile.

Metformin C4 Health should be stored at ambient temperature, preferably below 25 °C, in a dry place. Keep the product in its original packaging, protect it from moisture, and store out of direct sunlight.

Metformin C4 Health is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablet (or other oral form) should be swallowed whole with a glass of water, unless otherwise directed by a healthcare provider.

The most serious risk is lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal impairment, hepatic disease, or hypoxia. Prompt medical attention is required if symptoms such as rapid breathing, muscle pain, or abdominal discomfort develop.

Metformin C4 Health is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin, acute or chronic metabolic acidosis, and in those receiving iodinated contrast agents without appropriate renal monitoring.